Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves Perrigo's Derma-Smoothe/FS Scalp Oil & Body Oil - Quick Facts

RELATED NEWS
Trade PRGO now with 

Perrigo Company (PRGO: Quote) announced it has received final approval from the U.S. FDA for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.

Derma-Smoothe/FS Scalp Oil and Derma-Smoothe/FS Body Oil are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks. Perrigo expects to begin shipments of both products next month.

Click here to receive FREE breaking news email alerts for Perrigo Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The United Nations Security Council (UNSC) on Thursday declared the ongoing Ebola outbreak in West Africa "a threat to international peace and security." Notably, the declaration was made in the Council's first emergency meeting on a public health issue. The fifteen-member Council also unanimously... Oracle Corp. said Thursday after the markets closed that its first quarter profit fell slightly from last year, hurt mainly by higher income tax expenses even as revenue increased 3%. The company's quarterly earnings per share, excluding items, also came in below analysts' expectations as did its quarterly revenue. After ending the previous session mostly higher following the Federal Reserve's monetary policy announcement, stocks saw further upside during trading on Thursday. The gains on the day lifted the Dow and the S&P 500 to new record closing highs.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.